Skip to main content Skip to search
+34 659 496 544

Investigación Traslacional en Cáncer Hereditario

Publicaciones

2024

Esteban-Villarrubia, J, Ballesteros, PA, Martín-Serrano, M, Vico, MR, Funes, JM, de Velasco, G, Castro, E, Olmos, D, Castellano, D, González-Billalabeitia, E (2024).

Mechanisms of Immune Evasion in PTEN Loss Prostate Cancer

Immuno. Review. 4(4):444-460.
[doi:10.3390/immuno4040028]
Castro, E, Ellis, J, Craigie, S, Haltner, A, Nazari, J, Niyazov, A, Samjoo, IA (2024).

Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer

ONCOLOGIST. Review.
[doi:10.1093/oncolo/oyae237]
Samjoo, IA, Disher, T, Castro, E, Ellis, J, Paganelli, S, Nazari, J, Niyazov, A (2024).

Predicting Treatment Effects from Surrogate Endpoints in Historical Trials in First-Line Metastatic Castration-Resistant Prostate Cancer

CLINICAL GENITOURINARY CANCER. Review. 22(5).
[doi:10.1016/j.clgc.2024.102137]
Cheng, HH, Shevach, JW, Castro, E, Couch, FJ, Domchek, SM, Eeles, RA, Giri, VN, Hall, MJ, King, MC, Lin, DW, Loeb, S, Morgan, TM, Offit, K, Pritchard, CC, Schaeffer, EM, Szymaniak, BM, Vassy, JL, Katona, BW, Maxwell, KN (2024).

BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review

JAMA oncology. Review.
[doi:10.1001/jamaoncol.2024.2185]
Castro, E (2024).

PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation Carriers

European Urology Focus. Editorial Material. 10(4):504-505.
[doi:10.1016/j.euf.2024.08.005]
Romero-Laorden, N, Lorente, D, de Velasco, G, Lozano, R, Herrera, B, Puente, J, López, PP, Medina, A, Almagro, E, Gonzalez-Billalabeitia, E, Villla-Guzman, JC, González-del-Alba, A, Borrega, P, Laínez, N, Fernández-Freire, A, Hernández, A, Rodriguez-Vida, A, Chirivella, I, Fernandez-Parra, E, López-Campos, F, Pacheco, MI, Morales-Barrera, R, Fernández, O, Villatoro, R, Luque, R, Hernando, S, Castellano, DC, Castro, E, Olmos, D (2024).

Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study

European Urology Oncology. Article. 7(3):447-455.
[doi:10.1016/j.euo.2023.09.015]
Bourlon, MT, Valdez, P, Castro, E (2024).

Development of PARP inhibitors in advanced prostate cancer

Therapeutic Advances in Medical Oncology. Review. 16.
[doi:10.1177/17588359231221337]
de la Maza, MDF, Gracia, JLP, Miñana, B, Castro, E (2024).

PARP inhibitors alone or in combination for prostate cancer

Therapeutic Advances in Urology. Review. 16.
[doi:10.1177/17562872241272929]
Calabrese, M, Saporita, I, Turco, F, Gillessen, S, Castro, E, Vogl, UM, Di Stefano, RF, Carfi, FM, Poletto, S, Farinea, G, Tucci, M, Buttigliero, C (2024).

Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer

International Journal Of Molecular Sciences. Review. 25(1).
[doi:10.3390/ijms25010078]

2023

Chávarri-Guerra, Y, Bourlon, MT, Rodríguez-Olivares, JL, Orozco, L, Bazua, D, Rodríguez-Faure, A, Alcalde-Castro, MJ, Castro, E, Castillo, D, Herzog, J, Weitzel, J (2023).

Germline DNA Repair Genes Pathogenic Variants Among Mexican Patients With Prostate Cancer

CLINICAL GENITOURINARY CANCER. Article. 21(5):569-573.
[doi:10.1016/j.clgc.2023.05.012]
Beije, N, Abida, W, Antonarakis, ES, Castro, E, de Wit, R, Fizazi, K, Gillessen, S, Hussain, M, Mateo, J, Morris, MJ, Olmos, D, Sartor, O, Sharp, A, Sweeney, CJ, de Bono, JS (2023).

PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.

EUROPEAN UROLOGY. Editorial Material. 84(3):253-256.
[doi:10.1016/j.eururo.2023.03.038]
Chi, KN, Sandhu, S, Smith, MR, Attard, G, Saad, M, Olmos, D, Castro, E, Roubaud, G, Gomes, AJPD, Small, EJ, Rathkopf, DE, Gurney, H, Jung, W, Mason, GE, Dibaj, S, Wu, D, Diorio, B, Urtishak, K, del Corral, A, Francis, P, Kim, W, Efstathiou, E (2023).

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

ANNALS OF ONCOLOGY. Article. 34(9):772-782.
[doi:10.1016/j.annonc.2023.06.009]
Smith, MR, Sandhu, S, George, DJ, Chi, KN, Saad, F, Thiery-Vuillemin, A, Stáhl, O, Olmos, D, Danila, DC, Gafanov, R, Castro, E, Moon, H, Joshua, AM, Mason, GE, Espina, BM, Liu, Y, Lopez-Gitlitz, A, Francis, P, Bevans, KB, Fizazi, K (2023).

Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects

Journal of Managed Care & Specialty Pharmacy. Article. 29(7):758-768.